0001553350-26-000075
SEC filingQ1 losses narrowed amid stable breathalyzer revenue from accelerated large orders offsetting rental discontinuation, with gross profit up on cost efficiencies, though SpinDetect development and rising borrowings pressure cash and bottom line.
SpinDetect progress provides a key operational signal, with beta testing of oral-fluid THC detection advancing toward 2026 commercial launch, followed by expansion into multi-drug panels and breath samples integrated with the LX9 breathalyzer. R&D intensity may taper post-development, but sales and marketing expenses are set to rise with added direct sales representatives and efforts. Success in profitability and cash flow break-even remains critical; failure could require additional borrowings or capital to sustain operations, especially if large order timing delays or SpinDetect uptake lags in this regulatory-sensitive sector.